Updated NETs Clinical Trials

Studies found on ClinicalTrials.gov by a search of: neuroendocrine NOT Melanoma NOT PMS | Recruiting, Not yet recruiting, Available Studies | Phase 2, 3, 4 | Last update posted in the last 30 days

  1. Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Metastatic Small Cell Neuroendocrine Carcinomas That Originate Outside the Lung

    Conditions:   Extrapulmonary Small Cell Neuroendocrine Carcinoma;   Recurrent Extrapulmonary Small Cell Neuroendocrine Carcinoma;   Recurrent Small Cell Neuroendocrine Carcinoma;   Small Cell Neuroendocrine Carcinoma
    Interventions:   Biological: Atezolizumab;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Other: Patient Observation
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting

  2. Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

    Conditions:   VHL Pancreatic Neuroendocrine Tumors;   Von Hippel-Lindau Disease;   Neuroendocrine Tumors
    Intervention:   Drug: 68-Gallium DOTATATE
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  3. Cabozantinib in High Grade Neuroendocrine Neoplasms

    Condition:   High Grade Neuroendocrine Neoplasms
    Interventions:   Drug: Cabozantinib;   Procedure: Blood for plasma biomarkers;   Procedure: Tissue biopsy
    Sponsors:   Washington University School of Medicine;   Exelixis
    Recruiting

  4. TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Mets

    Conditions:   Neuroendocrine Tumors;   Liver Metastases
    Intervention:   Radiation: TheraSpheres Selective Internal Radiation Therapy (SIRT)
    Sponsors:   Imperial College London;   Biocompatibles UK Ltd, a BT International group company
    Recruiting

  5. Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

    Conditions:   Neuroendocrine Tumors;   Neuroendocrine Tumor Grade 3;   Neuroendocrine Carcinoma;   Neuroendocrine Neoplasm
    Interventions:   Drug: Chidamide;   Drug: Sintilimab
    Sponsors:   Peking Union Medical College Hospital;   The First Affiliated Hospital of Xiamen University;   Harbin Medical University
    Recruiting

  6. Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

    Conditions:   Metastatic Malignant Neoplasm in the Liver;   Neuroendocrine Neoplasm
    Interventions:   Procedure: Arterial Embolization;   Biological: Pembrolizumab;   Biological: Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate;   Device: Yttrium-90 Microsphere Radioembolization
    Sponsors:   Nicholas Fidelman, MD;   Merck Sharp & Dohme Corp.;   BTG International Inc.
    Recruiting

  7. Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET) (MK-6482-015)

    Conditions:   Pheochromocytoma/Paraganglioma;   Pancreatic Neuroendocrine Tumor
    Intervention:   Drug: Belzutifan
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting

  8. Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

    Conditions:   Small Cell Neuroendocrine Carcinoma;   Prostate Cancer;   Small Cell Carcinoma
    Interventions:   Drug: Apalutamide;   Biological: Cetrelimab
    Sponsors:   Rahul Aggarwal;   Janssen Scientific Affairs, LLC
    Not yet recruiting

  9. Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

    Conditions:   Atypical Carcinoid Tumor;   Carcinoid Tumor;   Functioning Pancreatic Neuroendocrine Tumor;   Intermediate Grade Lung Neuroendocrine Neoplasm;   Locally Advanced Pancreatic Neuroendocrine Tumor;   Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm;   Low Grade Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Neoplasm;   Metastatic Digestive System Neuroendocrine Tumor G1;   Metastatic Pancreatic Neuroendocrine Tumor;   Metastatic Thymic Neuroendocrine Neoplasm;   Neuroendocrine Neoplasm;   Non-Functioning Pancreatic Neuroendocrine Tumor;   Pancreatic Serotonin-Producing Neuroendocrine Tumor;   Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7;   Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7;   Stage IV Digestive System Neuroendocrine Tumor AJCC v7
    Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  10. Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas

    Condition:   Advanced or Metastatic EP-NEC
    Interventions:   Drug: Camrelizumab;   Drug: Etoposide;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Apatinib
    Sponsor:   Huazhong University of Science and Technology
    Not yet recruiting

  11. Open-Label Surufatinib in European Patients With NET

    Conditions:   Neuroendocrine Tumours;   Neuroendocrine Tumour of the Lung;   Small Intestinal NET
    Intervention:   Drug: Surufatinib
    Sponsor:   Hutchison Medipharma Limited
    Recruiting

  12. Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases

    Conditions:   Neuroendocrine Tumor;   Liver Metastases;   Neuroendocrine Gastroenteropancreatic Tumour
    Interventions:   Procedure: Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection;   Procedure: Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection;   Drug: LUTATHERA® by intra-arterial hepatic (IAH) injection;   Procedure: Scan
    Sponsors:   University Hospital, Bordeaux;   Advanced Accelerator Applications
    Recruiting

  13. Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression

    Conditions:   Neuroendocrine Tumors;   Progesterone Receptor Positive Tumor;   Estrogen Receptor Positive Tumor
    Intervention:   Drug: Tamoxifen 20 mg
    Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
    Recruiting

  14. Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

    Conditions:   Gastroenteropancreatico Tumors;   Neuroendocrine Tumors;   Neuroendocrine Neoplasms
    Interventions:   Drug: Lu-177-DOTATATE;   Drug: Olaparib;   Diagnostic Test: Ga dotatate scanning;   Diagnostic Test: FDG-PET scanning
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting

  15. Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

    Conditions:   SCLC;   Small Cell Cancer;   Advanced Solid Tumor;   High Grade Neuroendocrine Cancers
    Interventions:   Drug: Lurbinectedin;   Drug: Berzosertib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  16. Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

    Conditions:   Advanced Adrenal Gland Pheochromocytoma;   Advanced Paraganglioma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Paraganglioma;   Unresectable Adrenal Gland Pheochromocytoma;   Unresectable Paraganglioma
    Interventions:   Drug: Olaparib;   Other: Quality-of-Life Assessment;   Drug: Temozolomide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  17. Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors

    Conditions:   Advanced Solid Tumor;   Metastatic Solid Tumor;   Urothelial Carcinoma;   Large Cell Neuroendocrine Carcinoma of the Lung;   Homologous Recombination Deficiency
    Intervention:   Drug: Lurbinectedin
    Sponsor:   Jazz Pharmaceuticals
    Not yet recruiting

  18. Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

    Conditions:   Bile Duct Cancer;   Gall Bladder Cancer;   Breast Cancer;   Neuroendocrine Tumors;   Ovarian Cancer;   Pancreatic Adenocarcinoma;   Soft Tissue Sarcoma;   Vulvar Cancer;   Prostate Cancer
    Interventions:   Drug: Atezolizumab;   Drug: Tivozanib
    Sponsors:   University of Florida;   Genentech, Inc.;   Aveo Oncology Pharmaceuticals
    Recruiting

  19. Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

    Conditions:   Bladder Small Cell Neuroendocrine Carcinoma;   Extensive Stage Lung Small Cell Carcinoma;   Extrapulmonary Small Cell Neuroendocrine Carcinoma;   Limited Stage Lung Small Cell Carcinoma;   Platinum-Resistant Lung Small Cell Carcinoma;   Platinum-Sensitive Lung Small Cell Carcinoma;   Prostate Small Cell Neuroendocrine Carcinoma;   Recurrent Lung Small Cell Carcinoma
    Interventions:   Drug: Berzosertib;   Drug: Topotecan Hydrochloride
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  20. 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

    Conditions:   Neuroendocrine Tumors;   Carcinoid Tumor;   Pulmonary Carcinoid Tumor;   Gastroenteropancreatic Neuroendocrine Tumor;   Vipoma;   Insulinoma;   Gastrinoma
    Intervention:   Drug: 177Lu-DOTATOC
    Sponsor:   British Columbia Cancer Agency
    Not yet recruiting

  21. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    Conditions:   Bladder Adenocarcinoma;   Bladder Clear Cell Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Neuroendocrine Carcinoma;   Bladder Small Cell Neuroendocrine Carcinoma;   Bladder Squamous Cell Carcinoma;   Bladder Urachal Adenocarcinoma;   Chromophobe Renal Cell Carcinoma;   Collecting Duct Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Neuroendocrine Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Neuroendocrine Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Metastatic Urethral Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IV Urethral Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor;   Urethral Clear Cell Adenocarcinoma
    Interventions:   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  22. Estrogen Administration for the Treatment of NASH in Postmenopausal Women

    Condition:   NASH - Nonalcoholic Steatohepatitis
    Interventions:   Drug: Estradiol patch;   Drug: Placebo
    Sponsor:   Massachusetts General Hospital
    Recruiting

  23. Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer

    Conditions:   Lung Atypical Carcinoid Tumor;   Lung Neuroendocrine Neoplasm;   Lung Non-Small Cell Squamous Carcinoma;   Minimally Invasive Lung Adenocarcinoma;   Neuroendocrine Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Large Cell Carcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Stage I Lung Cancer AJCC v8;   Stage IA1 Lung Cancer AJCC v8;   Stage IA2 Lung Cancer AJCC v8;   Stage IA3 Lung Cancer AJCC v8;   Stage IB Lung Cancer AJCC v8;   Stage IIA Lung Cancer AJCC v8
    Interventions:   Biological: Nivolumab;   Radiation: Stereotactic Body Radiation Therapy
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  24. Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

    Conditions:   Castration-Resistant Prostate Carcinoma;   Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Prostate Adenocarcinoma;   Metastatic Prostate Small Cell Neuroendocrine Carcinoma;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8
    Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Drug: Erdafitinib
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  25. Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer

    Conditions:   Appendix Carcinoma;   Colon Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Malignant Digestive System Neoplasm;   Pancreatic Carcinoma;   Rectal Carcinoma;   Small Intestinal Carcinoma;   Anal Carcinoma;   Digestive System Carcinoma;   Digestive System Neuroendocrine Tumor;   Pancreatic Neuroendocrine Tumor
    Interventions:   Procedure: Acupuncture Therapy;   Procedure: Acupressure Therapy;   Procedure: Oral Cryotherapy;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
    Sponsors:   University of Washington;   National Cancer Institute (NCI);   The Safeway Foundation
    Recruiting

  26. A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

    Conditions:   Colorectal Cancer Not MSI-H or MMR-deficient;   GIST;   Oesophageal or Gastric Carcinoma;   Biliary Tract Cancer;   Hepatocellular Carcinoma;   Soft-tissue Sarcoma;   Thyroid Cancer;   Gastro-enteropancreatic Neuroendocrine Tumor;   Non-small Cell Lung Cancer;   Solid Tumor, Adult
    Interventions:   Drug: Phase 1 : Regorafenib;   Drug: Phase 1 : Avelumab;   Drug: Phase 2 : Regorafenib;   Drug: Phase 2 : Avelumab;   Drug: Phase 2: low-dose Regorafenib
    Sponsors:   Institut Bergonié;   Bayer;   Merck KGaA, Darmstadt, Germany
    Recruiting

  27. Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

    Conditions:   RET-altered Non Small Cell Lung Cancer;   Medullary Thyroid Cancer;   RET-altered Papillary Thyroid Cancer;   RET-altered Colon Cancer;   RET-altered Solid Tumors;   Lung Neoplasm;   Carcinoma, Non-Small-Cell Lung;   Thyroid Diseases;   Thyroid Neoplasm;   Thyroid Cancer, Papillary;   Carcinoma, Neuroendocrine;   Respiratory Tract Neoplasms;   Thoracic Neoplasms;   Neoplasms by Site;   Neoplasms;   Lung Diseases;   Respiratory Tract Disease;   Carcinoma, Bronchogenic;   Bronchial Neoplasms;   Endocrine System Diseases;   Endocrine Gland Neoplasm;   Head and Neck Neoplasms;   Adenocarcinoma, Papillary;   Adenocarcinoma;   Carcinoma;   Neoplasms, Glandular and Epithelial;   Neoplasms by Histologic Type;   Neuroendocrine Tumors;   Neuroectodermal Tumors;   Neoplasms, Germ Cell and Embryonal;   Neoplasms, Nerve Tissue;   Colonic Neoplasms;   Colorectal Neoplasms;   Intestinal Neoplasms;   Gastrointestinal Neoplasms;   Digestive System Neoplasm;   Digestive System Disease;   Gastrointestinal Disease;   Colonic Diseases;   Intestinal Disease
    Intervention:   Drug: pralsetinib (BLU-667)
    Sponsor:   Hoffmann-La Roche
    Recruiting

  28. A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

    Condition:   Medullary Thyroid Cancer
    Interventions:   Drug: Selpercatinib;   Drug: Cabozantinib;   Drug: Vandetanib
    Sponsors:   Loxo Oncology, Inc.;   Eli Lilly and Company
    Recruiting

  29. Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

    Conditions:   Advanced Solid Tumors;   Glioblastoma;   Soft Tissue Sarcoma (Excluding GIST);   Endometrial Carcinoma;   Epithelial Ovarian Carcinoma;   Mesothelioma;   Gastroenteropancreatic Neuroendocrine Tumor;   SCLC;   Gastric Carcinoma;   Pancreatic Adenocarcinoma;   Colorectal Carcinoma;   Neuroendocrine Tumors
    Interventions:   Drug: Lurbinectedin;   Drug: Irinotecan
    Sponsor:   PharmaMar
    Recruiting

  30. A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

    Conditions:   Locally Advanced Solid Tumors;   Metastatic Solid Tumors
    Intervention:   Drug: Oral repotrectinib (TPX-0005)
    Sponsor:   Turning Point Therapeutics, Inc.
    Recruiting

  31. XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

    Condition:   Metastatic Castration-Resistant Prostate Cancer
    Interventions:   Combination Product: XmAb20717 + carboplatin + cabazitaxel;   Combination Product: XmAb20717 + olaparib;   Biological: XmAb20717 monotherapy
    Sponsor:   Xencor, Inc.
    Recruiting

  32. Study in Patients With Advanced Cancers Associated With Expression of DLL3 Who Have Failed Standard Available Therapy

    Condition:   Small-cell Lung Cancer
    Intervention:   Drug: HPN328
    Sponsor:   Harpoon Therapeutics
    Recruiting

  33. A Study of LOXO-292 in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

    Conditions:   Non-Small Cell Lung Cancer;   Medullary Thyroid Cancer;   Colon Cancer;   Any Solid Tumor
    Intervention:   Drug: LOXO-292
    Sponsors:   Loxo Oncology, Inc.;   Eli Lilly and Company
    Recruiting

  34. Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

    Condition:   Metastatic Castration-Resistant Prostate Cancer
    Interventions:   Biological: Pembrolizumab 200 mg;   Drug: Olaparib 400 mg;   Drug: Docetaxel 75 mg/m^2;   Drug: Prednisone 5 mg;   Drug: Enzalutamide 160 mg;   Other: Dexamethasone 8 mg;   Drug: Olaparib 300 mg;   Drug: Abiraterone acetate 1000 mg;   Drug: Lenvatinib;   Biological: Pembrolizumab/Vibostolimab coformulation;   Drug: Carboplatin;   Drug: Etoposide
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting

  35. Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study

    Conditions:   Advanced Renal Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Clear Cell Renal Cell Carcinoma;   Collecting Duct Carcinoma;   Kidney Medullary Carcinoma;   Metastatic Malignant Neoplasm in the Bone;   Papillary Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8;   Unclassified Renal Cell Carcinoma
    Interventions:   Drug: Cabozantinib S-malate;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radium Ra 223 Dichloride
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  36. Adjuvant Avelumab in Merkel Cell Cancer

    Conditions:   Stage III Merkel Cell Carcinoma AJCC v8;   Stage IIIB Merkel Cell Carcinoma AJCC v8;   Stage IIIA Merkel Cell Carcinoma AJCC v8
    Interventions:   Drug: Avelumab;   Other: Peripheral Blood Collection;   Other: Placebo
    Sponsors:   University of Washington;   EMD Serono
    Recruiting

  37. Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

    Conditions:   Merkel Cell Carcinoma;   Skin Cancer
    Interventions:   Drug: Nivolumab;   Drug: Ipilimumab;   Radiation: Stereotactic Body Radiation Therapy (SBRT)
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Bristol-Myers Squibb
    Recruiting

  38. Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

    Condition:   Neurofibromatosis Type 2
    Interventions:   Drug: REC-2282;   Drug: Placebo
    Sponsor:   Recursion Pharmaceuticals Inc.
    Not yet recruiting

  39. BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

    Conditions:   Hepatocellular Carcinoma;   Squamous Cell Carcinoma of the Lung;   Merkel Cell Carcinoma;   Liposarcoma
    Intervention:   Biological: CAR-GPC3 T Cells
    Sponsors:   SOTIO, LLC;   SOTIO Biotech
    Not yet recruiting

  40. A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory Trial

    Condition:   Advanced or Metastatic Paraganglioma/ Pheochromocytoma
    Intervention:   Drug: Anlotinib
    Sponsor:   Nanjing First Hospital, Nanjing Medical University
    Recruiting

  41. LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)

    Conditions:   Paraganglioma;   Pheochromocytoma
    Intervention:   Drug: Lanreotide
    Sponsors:   Antonio Fojo;   Ipsen
    Recruiting